Knowledge on the molecular background of mitochondrial disorders has accumulated during the past two decades, but clinical and molecular features of mitochondrial cardiomyopathies (CMPs) are only starting to be characterized. We studied the detailed cardiologic phenotype of patients with adult-onset CMPs associated with mitochondrial DNA (mtDNA) mutations and their relatives, from three families. We identified a pathogenic T3258C
Introduction
Mitochondrial DNA (mtDNA) mutations are a frequent cause of mitochondrial disease of adult age. Up to date, more than 120 pathogenic mtDNA point mutations have been described. 1 MtDNA encodes 13 subunits of the respiratory chain (RC) enzymes, and its mutations cause RC deficiency and compromised oxidative ATP production. Therefore, tissues highly dependent on oxidative ATP-production, such as the skeletal muscle, heart, brain and neurosensory organs, are often affected by mtDNA mutations. However, mtDNA defects may manifest in a highly tissue specific manner, which cannot be explained by the mere ATP-deficiency. 1, 2 Recent reports suggest an important role for mitochondrial translation defects on early childhood cardiomyopathies (CMPs). [3] [4] [5] However, molecular backgrounds of mitochondrial CMPs of adult age are still quite poorly known. Recessive ANT1 mutations were described to cause early-adulthood CMP in one pedigree, 6 and multiple mtDNA deletions were associated with CMP in a family with dominantly inherited dilated CMP.
7 A3243G mutation in tRNA Leu(UUR) of mtDNA has been occasionally reported to include CMP as part of the disease manifestation. [8] [9] [10] [11] [12] [13] This mutation typically manifests as mitochondrial myopathy and encephalopathy 14 or as maternally inherited diabetes and deafness 15 with high populationdependent frequency: from 1:420 in Australia to ~1:5000 -1:10,000 in UK and Finland. 9, 16, 17 We report here the molecular genetics and presentation of mitochondrial myopathy with hypertrophic CMP in three families.
Materials and Methods

Patients
All the patient studies were done according to the Helsinki Declaration, with written informed consent from the patients. All subjects were of Finnish origin; Figure 1 illustrates their pedigrees. All individuals, whose mutation percentage is shown in the pedigree, were also clinically examined. Altogether 12 subjects underwent detailed neurologic and cardiologic examinations and from two deceased patients data was obtained from hospital records. Table 1 
Family 1
The proband (II:2) is a 39-year old male, who presented at the age of 35 years with exercise-induced muscle pain, proximal leg weakness, dyspnea and sinus tachycardia 106/min and S3 in cardiac auscultation. He had been prescribed diuretics due to swelling of the ankles. Figure 2A shows the electrocardiogram (ECG). Serum pro-B-type natriuretic peptide (pro-BNP) concentration was elevated but thorax X-ray did not show pulmonary congestion. The main echocardiographic finding was nonobstructive left-ventricular hypertrophy (LVH; Figure 2A , Table 2 ). Doppler examination suggested elevated filling pressures. Magnetic resonance spectroscopy of the brain showed lactate increase in the thalamus, but no neurological signs or symptoms. Skeletal muscle sample showed that 20% of muscle fibers were cytochrome-c-oxidase (COX)-negative, succinate dehydrogenase positive, strongly supporting the diagnosis of mitochondrial dysfunction also underlying his cardiomyopathy. Family history was negative for mitochondrial diseases or cardiomyopathy. During clinical follow-up, his cardiologic condition has remained stable, without arrhythmias or dyspnea. Left ventricular walls have remained thickened, but the early peak diastolic LV/mitral annular velocity (E/Em) ratios have nearly normalized.
Family 2
The proband (III:6) is a woman with diabetes mellitus, sensorineural hearing impairment and depression. At the age of 51 years she developed acute pulmonary edema, hypertension and lactacidemia. Despite regular pulse and normal sized heart, serum troponin T and creatinine kinase-MB isoenzyme mass (CK-Mbm) levels were elevated (Table 1) . ECG and echocardiography demonstrated LVH, with diminished systolic function and restrictive hemodynamics ( Figure 2B , Table 2 ). Coronary angiography demonstrated 70% stenosis in the proximal left anterior descending coronary artery (LAD), a total occlusion of middle LAD with collaterals from the right coronary artery, and 50% and 80% stenosis in first diagonal branch of LAD (D1) and second diagonal branch of LAD (D2), respectively. LV end diastolic pressure was 18 mmHg. Medical treatment of coronary artery disease was chosen. The diagnosis of mitochondrial contribution in hypertrophic CMP was strongly supported by histological results of skeletal muscle biopsy samples, showing over 30% of COX-negative muscle fibers, many of them also showing the ragged-red fiber appearance, typical and diagnostic for mitochondrial myopathy. In followup she developed episodes of cardiac decompensation induced by atrial flutter (ventricular response of 90/min) or fibrillation (~110/min) alternating with sinusbradycardia. These episodes were accompanied with metabolic acidosis. Hemodynamics improved and lactacidemia subsided after sinus rhythm was restored. Plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration was high, up to 25,505 ng/L, but decreased upon compensation. She received a physiologic pacemaker. Patient II:5 was a woman who at 66 years of age had an episode of cardiac decompensation with atrial fibrillation and left bundle branch block, but no ventricular tachycardia. On echocardiography LV ejection fraction was 40%. She had mild renal failure and serum NT-proBNP concentration was high (Table 1) . Brain computed tomography revealed old infarctions in both hemispheres and in cerebellum; she was diagnosed with multi-infarction dementia. Coronary angiography had been carried out at the age of 65 years, it had revealed one significant stenosis of the left coronary circumflex branch that was treated by percutaneous coronary intervention and stenting. At 68 years, she was hospitalized because of chest pain; her blood pressure was 95/60 mmHg, she had sinus tachycardia (113/min), and an enlarged heart with pulmonary venous congestion. Echocardiography was not performed. The patient succumbed soon there- 
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Age at the last examination is reported. Abbreviations: CAD, coronary artery disease; NA, not available; RR, blood pressure; NT-proBNP, N-terminal pro B-type natriuretic peptide; CK, creatinine kinase; CKMBm, CK-MB isoenzyme mass; TnT, troponine T subunit; ECG, electrocardiography; AV, atrioventricular; LVH, left ventricular hypertrophy; LAH, left atrial hypertrophy; LBBB, left bundle branch block; prx, paroxysmal, paroxysms; %b, mutation % in blood; %m, mutation % in skeletal muscle; %uec, mutation % in urinary epithelial cells. 
Family 3
The proband (II:2). At 56 years of age this short and lean woman with asthma and hearing impairment (since 33 years of age) had her first episode of atrial fibrillation. She was slightly hypertensive, ECG showed strain and pulse rate of 64/min, and CK-MBm, troponin T and creatinine concentrations were slightly elevated (Table 1) . Echocardiography showed LVH, with ejection fraction (EF) of 46% and moderate mitral and tricuspid regurgitation ( 
Echocardiography and cardiac magnetic resonance imaging
Original digital echocardiographic data were available in 10 out of 12 cases. In two cases (Family 1, I:2; Family 3, II:2) data were obtained from medical records. We regarded left ventricular wall thickness exceeding 10 mm abnormal. Relative wall thickness (RWT) was calculated by the formula (2XPWTd)/ LVIDd. RWT>0.42 was considered abnormal. Of the tissue Doppler velocities, mitral inflow E wave>1 m/s and E/Em>15 were considered indicative for restrictive hemodynamics. Cardiac magnetic resonance imaging (MRI) was performed with 1.5 T MR imager (Avanto, Siemens, Erlangen, Germany). Breath-hold cine images were performed using retrospectively gated segmented true fast imaging with steady-state free precession techniques. Cine MR images were obtained in 4-chamber, 3-chamber and short-axis planes covering both ventricles. Delayed enhancement images were acquired 15 min after injection of contrast agent (gadoterate meglumine 0.1 mmol/kg) in the same views as for cine images, using inversion recovery turbo fast-low angle shot. Inversion time was optimized for each measurement to null the signal intensity of normal myocardium (240-360 ms). Cine images were analyzed with Argus application (Siemens) developed for this purpose. Delayed enhanced images were analyzed visually.
mtDNA analyses
Total DNA from snap-frozen muscle tissue, blood samples or cultured fibroblasts was extracted by phenol-chlorophorm and precipitated with ethanol, according to standard methods. The full mtDNA sequence (for index patient II:2 of family 1), was determined by high-throughput sequencing as described by Pietiläinen et al., 18 using revised Cambridge sequence of complete human mtDNA (NC_012920.1) as reference. Sequence processing and analysis was done with Sequencher 4.5 software (GeneCodes Corp., Ann Arbor, MI, USA). For mutant T3258C mtDNA quantification and for A3243G mutant detection and quantification we utilized solidphase minisequencing, as studied by Suomalainen and Syvänen. 19 The primer sequences for T3258C were as follows: F: 5' Biotin-ACCCACCCAAGAACAGGGTTTGTTA 3' R:
5' CATGGGTATGTTGTTAAGAAGAG-GAATTGAACCTC 3' R-detection: 5' ACTG-TAAAGTTTTAAGTTTT 3'. Respiratory chain protein analysis of fibroblasts
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Primary fibroblast cell lines of patient II:2 were cultured according to standard conditions in 5% CO 2 , Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum. Mitochondrial membranes with intact respiratory chain complexes were extracted from a total of about four million cells as previously described. 20 The samples were separated on a 6-15% blue native polyacrylamide gel electrophoresis 21 and blotted onto a polyvinylidene fluoride membrane (EMD Millipore Corp., Billerica, MA, USA). For protein detection, we used monoclonal antibodies (Mitosciences, Eugene, OR, USA) against the 39 kDa subunit of Complex I, and 70 kDa-Ip subunit of Complex II. In-gel histochemical Complex I holoenzyme activity of the patient's fibroblasts was measured after blue native electrophoresis, as previously described. 22 Complex I activity was quantified by calculating the band intensity against the protein amount of Complex II, in a parallel gel.
Results
DNA analysis
MtDNA sequence analysis of patient II:2 from family 1 showed a heteroplasmic T to C transition at the highly conserved nucleotide position 3258 within the mitochondrial tRNA Leu (UUR) gene. No other heteroplasmic or potentially pathogenic variants were found in the analysis (variants excluded as pathogenic, if present in the mitochondrial polymorphic variant databases in over 1% of individuals; www.mitomap.org, www.mtdb.igb.uu.se). The proportion of the mutant mtDNA was 88% of total mtDNA in the skeletal muscle, 70% in the fibroblasts and 59% in blood. The mother of the proband (I:2) also carried the heteroplasmic mutation, in a lower amount of 34% of total mtDNA in her blood, confirming maternal inheritance. In families 2 and 3, the index patients and their maternal relatives had the A3243G transition within tRNA Leu (UUR) of mtDNA in variable amounts ( Figure 1 , Table  1 ). Both T3258C and A3243G mutations have previously been proven to be unequivocally pathogenic, based on both genetic and biochemical data; 14, 23, 24 mutant mtDNA amounts were lower in blood than in skeletal muscle, which is a known feature of A3243G mutant mtDNA: progressive loss of mutant mtDNA from blood occurs during aging. 25 An overview of the cardiac findings Table 1 summarizes the clinical findings  and Table 2 the echocardiographic findings. Of 14 individuals with mtDNA mutations or maternally related likely carriers, eight had cardiac symptoms, mainly palpitations, chest pain and dyspnea. Five subjects had paroxysmal or chronic atrial fibrillation. None had remarkable atrioventricular conduction disturbances or documented ventricular arrhythmias. Two patients had ECG changes compatible with LVH.
Echocardiography showed normal sized left ventricles, but thickened left ventricular walls (>10 mm) in eight subjects, aged 39-69 years (mean 54.5 years), whereas those with normal left ventricular wall thickness were younger, aged 20-36 years (mean 24.8). Relative wall thickness was increased in 8/12 (67%) subjects, aged 20-69 years (mean 48.4). Those with normal RWT were aged 27-69 years (mean 41.5). None of the subjects had left ventricular outflow tract obstruction. Prominent LVH was associated with diastolic dysfunction, even restrictive hemodynamics. The systolic function was mainly normal at rest.
Three female patients, aged 58-68 years, died of rapidly developing heart failure. Two patients had sinustachycardia and one atrial fibrillation in terminal phase. In addition, one subject has had several episodes of acute heart failure precipitated by atrial fibrillation. The tachyarrhythmias typically associated with lactic acidosis and rapidly rising plasma NTproBNP level. The response to inotropes was poor.
Cardiac MRI of patient II:2, family 1, demon- strated preserved end-diastolic and -systolic volumes and functions, irregularly thickened left ventricular walls and increased global mass of the heart 26, 27 ( Figure 3 ). Six subjects had hypertension, five had diabetes and two had coronary artery disease verified by angiography or autopsy.
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Respiratory chain protein analysis
Blue native gel electrophoresis, separating respiratory chain complexes as whole functional enzyme complexes in native gel, indicated a decreased amount of fully assembled complex I (containing seven mtDNA-encoded subunits, the translation of which is dependent on functional mitochondrial tRNAs), when compared to Complex II (fully encoded by nuclear genes, and therefore unaffected by mitochondrial DNA defects). Furthermore, in-gel Complex-I enzyme activity assay in the native gel showed of marked Complex-I deficiency in the patient with T3258C mutation (Figure 4 ). This result supported mitochondrial respiratory chain dysfunction caused by T3258C mutant mtDNA.
Discussion
We report here maternally inherited mitochondrial tRNA Leu (UUR) mutations A3243G and T3258C in patients with adult-onset hypertrophic CMP and show that their oligosymptomatic mutation-carrying relatives also often have cardiac manifestations. Hypertrophic CMP was the main manifestation of the disease in our three families. We show that atrial arrhythmias in these patients may lead to rapidly progressive cardiac insufficiency, lethal in some of our patients. The A3243G change is the most commonly found mtDNA mutation, originally described to cause mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS), but most often manifesting as maternally inherited diabetes and deafness. 14, 15 Typical for A3243G disorders is the wide variation in clinical manifestations, but only few case reports of CMP as a major presenting manifestation exist. [8] [9] [10] [11] [12] [13] We conclude that cardiac manifestations associated to A3243G and T3258C mutations, despite the common occurrence of the former, 9, 16, 17 are not well known among physicians. If diagnosed early, the malignant disease course of these mitochondrial CMPs upon atrial fibrillation could be affected by prompt intervention.
The heteroplasmic T3258C tRNA Leu (UUR) mutation of mtDNA has previously been described to cause MELAS, similar to A3243G mutation, but no CMP. 23, 28 However, the clear finding of mitochondrial myopathy in the patients' muscle and Complex-I deficiency in fibroblasts indicate that the T3258C-disease affects several tissue types, and is likely to underlie the cardiac symptoms as well in the patient. The clinical manifestations associated with tRNA mutations of mtDNA are typically extremely variable. 1 The cardiac manifestations co-segregating in the large pedigrees with tRNA Leu (UUR) mutation A3243G, and clear findings of mitochondrial myopathy in the muscle also strongly support the causative role of this mutation underlying CMP of our patients. Furthermore, the number of reported patients and biochemical evidence have clearly established the pathogenic role of both T3258C and A3243G: they lead to tRNA Leu (UUR) dysfunction, deficient mitochondrial protein translation and respiratory chain deficiency. 23 Our findings show that mtDNA mutations should be considered as possible causes of hypertrophic concentric CMPs, even if neurological or muscle symptoms were not present.
Previous studies have suggested that the risk of developing LVH is related to the general severity of the phenotype of the mitochondrial disease and to a lesser degree to age. 13 However, in our patients, LVH was the leading manifestation of the disease, progressive by age. Tachycardia, especially atrial fibrillation or flutter led rapidly to deterioration of the left ventricular systolic function and florid, sometimes fatal heart failure, associated with metabolic acidosis. Hypertrophic CMP caused by sarcomeric mutations, with substantial left ventricular wall thickening, lead often to ventricular tachyarrhythmia or left ventricular outflow tract obstruction. None of our patients had documented ventricular tachyarrythmias or obstruction, or atrioventricular conduction abnormality, although their left ventricular wall thickness was comparable to that in typical sarcomeric CMPs. End-stage CMP in our patients was associated with fibrosis, indicating cardiomyocyte degeneration. Our results show that mitochondrial CMP patients are particularly vulnerable to tachycardia, and that imminent intervention for atrial tachycardias is important.
Typical mitochondrial CMPs are nonobstructive and concentric, 11, 13, 29 but also dilated CMP has been described. 30, 31 In our patients, the decrease of left ventricular systolic function was not associated with an increased left ventricular end diastolic dimension, but instead, the left ventricular walls were thickened, especially upon acute decompensation. The cardiac MRI showed diffuse mild intensity enhancement, suggestive of edema, in hypertrophic areas, mainly in basal anteroseptal and posterolateral wall. MRI findings in hypertrophic sarcomeric CMPs typically show delayed mid-myocardial enhancement in hypertrophic parts of septum and at the junctions of interventricular septum and right ventricle. 32 In Anderson-Fabry CMP enhancement locates predominantly in the posterolateral wall. In sarcoidosis thickening and enhancement of ventricular wall can be found in most cases in the same area as in our patient, basal septum and laterobasal wall, but typically patchy and nodular mid-myocardial and subepicardial areas exist. 33 These findings suggest that different molecular causes of hypertrophic CMP may affect different regions of myocardium.
Both T3258C and A3243G mutations in tRNA Leu(UUR) lack the normal taurine-containing modification (5-taurinomethyluridine) at the anticodon wobble position, leading to inefficient and imprecise codon recognition and aminoacylation. 23 The defective mitochondrial translation, due to lack of leucine incorporation and misincorporation of phenylalanine in place of leucine to proteins, 34 is supported by the complex-I deficiency in our T3258C patient cells. Complex I contains the highest amount of leucine, and has the highest number of mtDNA-encoded subunits. Accordingly, complex I deficiency has been reported to be typical for A3243G and A3260G mutation in tRNA Leu (UUR) , the latter also associated with mitochondrial CMP. [35] [36] [37] Occasional CMP patients with tRNA Ile , tRNA Gly and tRNA Leu (CUN) mutations have been reported. 35, [38] [39] [40] Why CMP is not, however, a common consequence of all mitochondrial tRNA mutations or not even always a manifestation of A3243G in all families remains unsolved.
Our study shows that patients with tRNA Leu(UUR) mutations need cardiologic evaluation and follow-up. The triad of diastolic dysfunction, atrial arrhythmias and metabolic acidosis may be life-threatening for these patients, and should be recognized especially in an acute setting: prompt treatment of tachycardia might prevent development of irreversible heart failure in mitochondrial disease patients. Furthermore, tRNA Leu(UUR) mutations should be screened in patients with hypertrophic CMP and metabolic acidosis, especially, if atrial arrhythmia provoked cardiac decompensation. 
